IN8bio reports 100% of evaluable patients in Phase 1 INB-100 trial remain in complete remission

IN8BIO, INC.

All 10 evaluable patients alive, progression-free, and in durable CR as of Nov 3, 2023; 6 relapse-free for over 1 year.
No dose-limiting toxicities observed; low-grade acute GVHD in 60% of patients.
Gamma-delta T cells expanded and persisted >365 days post single dose; dose response shows 48.9x greater at day 60 for DL 2 vs HSCT alone.
Two patients progression-free for over 3 years; individual follow-up ranges 4.9 to 42.7 months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.